Clinuvel Pharmaceuticals Ltd:主席致辭
Clinuvel Pharmaceuticals Ltd:加拿大在EPP中提交了SCENESSE的新藥申請
Clinuvel Pharmaceuticals Ltd:SCENESSE數據將在全球卟啉病會議上公佈
Clinuvel Pharmaceuticals Ltd:股東周年大會會議時間變更
Clinuvel Pharmaceuticals Ltd:董事的首次利息通知-Pearl Grimes
Clinuvel Pharmaceuticals Ltd:董事的初步利息通知-Guy van Dievoet
Clinuvel Pharmaceuticals Ltd:董事的初步利息通知——馬修·普林格爾
Clinuvel Pharmaceuticals Ltd:CLINUVEL 投資者網絡研討會
Clinuvel Pharmaceuticals Ltd:公司治理聲明
Clinuvel Pharmaceuticals Ltd:附錄 4G
Clinuvel Pharmaceuticals Ltd:股息/分配-CUV
Clinuvel Pharmaceuticals Ltd:白癜風和業務更新
Clinuvel Pharmaceuticals Ltd:年度業績網絡研討會
Clinuvel Pharmaceuticals Ltd:阿法諾肽協助紫外線損傷後的DNA修復反應
Clinuvel Pharmaceuticals Ltd:SCENESSE獲得了歐洲治療孤兒藥物認定
Clinuvel Pharmaceuticals Ltd:對於皮膚較淺的帕金森患者,afamelanotide是一種有效的治療方法。
Clinuvel Pharmaceuticals Ltd:CLINUVEL通訊 III - 2024年6月
Clinuvel Pharmaceuticals Ltd:CLINUVEL 取消了對青少年 EPP 的標籤擴展
Clinuvel Pharmaceuticals Ltd:CLINUVEL 和 Valentech 進入拉丁美洲合作伙伴關係
Clinuvel Pharmaceuticals Ltd:SCENESSE XP 歐洲孤兒藥認定
暫無數據
暫無數據